Loading
Life sciences · Journal article
Bulletin of the Korean Chemical Society · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Tumor hypoxia severely compromises conventional photodynamic therapy (PDT) and immunotherapy (IT) by restricting oxygen‐dependent reactive oxygen species (ROS) generation and upregulating immune inhibition‐related factors. Type‐I photosensitizers (PSs) offer an effective solution for PDT by producing radical species through electron‐transfer pathways under oxygen‐deficient conditions. Additionally, hypoxia‐tolerant PDT‐induced irreversible cell damage causes immunogenic cell death (ICD) that could initiate an immune response. In the hypoxic tumor environment, Type‐I PSs have achieved the simultaneous enhancement of PDT and IT effects. This perspective summarizes recent advances in hypoxia‐tolerant PDT and photoimmunotherapy. We also summarize several methods for enhancing intramolecular charge transfer in Type‐I PSs through structural adjustment, the pathways for inducing immune responses by Type‐I PSs, as well as highly biologically safe phototherapy strategies. Finally, another perspective is proposed for advanced Type‐I PSs with high therapeutic efficacy and low toxicity.